The ADP-ribosyltransferase domain of the effector protein exos inhibits phagocytosis of Pseudomonas aeruginosa during pneumonia

mBio

Volumn 5, Issue 3, 2014, Pages

  Rangel, Stephanie M ^a   Logan, Latania K ^a,b   Hausera, Alan R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BACTERIAL PROTEIN; GUANOSINE TRIPHOSPHATASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN EXOS; UNCLASSIFIED DRUG; BACTERIAL TOXIN; EXOENZYME S;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HOSPITAL ACQUIRED PNEUMONIA; IMMUNOBLOTTING; INTERNALIZATION; LUNG LAVAGE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; TYPE III SECRETION SYSTEM; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; ENZYMOLOGY; GENETICS; HUMAN; IMMUNOLOGY; MICROBIOLOGY; PROTEIN TERTIARY STRUCTURE; PSEUDOMONAS INFECTION;

ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL PROTEINS; BACTERIAL TOXINS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; PHAGOCYTOSIS; PNEUMONIA; PROTEIN STRUCTURE, TERTIARY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84903976203     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01080-14     Document Type: Article

References (47)

1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. http://www. cdc. gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508. pdf.
2. Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C, Gibert C. 1989. Nosocomial pneumonia in patients receiving continuous me-chanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am. Rev. Respir. Dis. 139: 877-884. http://dx. doi. org/10. 1164/ajrccm/139. 4. 877.
3. George DL, Falk PS, Wunderink RG, Leeper KV, Jr, Meduri GU, Steere EL, Corbett CE, Mayhall CG. 1998. Epidemiology of ventilator-acquired pneumonia based on protected bronchoscopic sampling. Am. J. Respir. Crit. Care Med. 158: 1839-1847. http://dx. doi. org/10. 1164/ajrccm. 158. 6. 9610069.
4. Rello J, Gallego M, Mariscal D, Soñora R, Valles J. 1997. The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 156: 196-200. http://dx. doi. org/10. 1164/ajrccm. 156. 1. 9607030.
5. Hauser AR. 2009. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat. Rev. Microbiol. 7: 654-665. http://dx. doi. org/10. 1038/nrmicro2199.
6. Wiener-Kronish JP, Sakuma T, Kudoh I, Pittet JF, Frank D, Dobbs L, Vasil ML, Matthay MA. 1993. Alveolar epithelial injury and pleural empyema in acute Pseudomonas aeruginosa pneumonia in anesthetized rabbits. J. Appl. Physiol. 75: 1661-1669.
7. Shaver CM, Hauser AR. 2004. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect. Immun. 72: 6969-6977.
8. Vance RE, Rietsch A, Mekalanos JJ. 2005. Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo. Infect. Immun. 73: 1706-1713. http://dx. doi. org/10. 1128/IAI. 73. 3. 1706-1713. 2005.
9. Hauser AR, Cobb E, Bodí M, Mariscal D, Vallés J, Engel JN, Rello J. 2002. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit. Care Med. 30: 521-528. http://dx. doi. org/10. 1097/00003246-200203000-00005.
10. Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J, Sawa T, Frank DW, Wiener-Kronish JP. 2001. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J. Infect. Dis. 183: 1767-1774. http://dx. doi. org/10. 1086/320737.
11. Feltman H, Schulert G, Khan S, Jain M, Peterson L, Hauser AR. 2001. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology (Reading, Engl.) 147: 2659-2669.
12. Goehring U-M, Schmidt G, Pederson KJ, Aktories K, Barbieri JT. 1999. The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPase-activating protein for Rho GTPases. J. Biol. Chem. 274: 36369-36372. http://dx. doi. org/10. 1074/jbc. 274. 51. 36369.
13. DiNovo AA, Schey KL, Vachon WS, McGuffie EM, Olson JC, Vincent TS. 2006. ADP-ribosylation of cyclophilin A by Pseudomonas aeruginosa exoenzyme S. Biochemistry 45: 4664-4673. http://dx. doi. org/10. 1021/bi0513554.
14. Maresso AW, Baldwin MR, Barbieri JT. 2004. Ezrin/radixin/moesin proteins are high affinity targets for ADP-ribosylation by Pseudomonas aeruginosa ExoS. J. Biol. Chem. 279: 38402-38408. http://dx. doi. org/10. 1074/jbc. M405707200.
15. Vincent TS, Fraylick JE, McGuffie EM, Olson JC. 1999. ADPribosylation of oncogenic Ras proteins by Pseudomonas aeruginosa exoenzyme S in vivo. Mol. Microbiol. 32: 1054-1064. http://dx. doi. org/10. 1046/j. 1365-2958. 1999. 01420. x.
16. Mustafi S, Rivero N, Olson JC, Stahl PD, Barbieri MA. 2013. Regulation of Rab5 function during phagocytosis of live Pseudomonas aeruginosa in macrophages. Infect. Immun. 81: 2426-2436. http://dx. doi. org/10. 1128/IAI. 00387-13.
17. Cowell BA, Chen DY, Frank DW, Vallis AJ, Fleiszig SMJ. 2000. ExoT of cytotoxic Pseudomonas aeruginosa prevents uptake by corneal epithelial cells. Infect. Immun. 68: 403-406. http://dx. doi. org/10. 1128/IAI. 68. 1. 403-406. 2000.
18. Garrity-Ryan L, Kazmierczak B, Kowal R, Comolli J, Hauser A, Engel JN. 2000. The arginine finger domain of ExoT contributes to actin cytoskeleton disruption and inhibition of internalization of Pseudomonas aeruginosa by epithelial cells and macrophages. Infect. Immun. 68: 7100-7113. http://dx. doi. org/10. 1128/IAI. 68. 12. 7100-7113. 2000.
19. Fleiszig SM, Wiener-Kronish JP, Miyazaki H, Vallas V, Mostov KE, Kanada D, Sawa T, Yen TS, Frank DW. 1997. Pseudomonas aeruginosamediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. Infect. Immun. 65: 579-586.
20. Frithz-Lindsten E, Du Y, Rosqvist R, Forsberg A. 1997. Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type IIIdependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments. Mol. Microbiol. 25: 1125-1139. http://dx. doi. org/10. 1046/j. 1365-2958. 1997. 5411905. x.
21. Barclay NG, Spurrell JC, Bruno TF, Storey DG, Woods DE, Mody CH. 1999. Pseudomonas aeruginosa exoenzyme S stimulates murine lymphocyte proliferation in vitro. Infect. Immun. 67: 4613-4619.
22. Jia J, Wang Y, Zhou L, Jin S. 2006. Expression of Pseudomonas aeruginosa toxin ExoS effectively induces apoptosis in host cells. Infect. Immun. 74: 6557-6570. http://dx. doi. org/10. 1128/IAI. 00591-06.
23. Kaufman MR, Jia J, Zeng L, Ha U, Chow M, Jin S. 2000. Pseudomonas aeruginosa mediated apoptosis requires the ADP-ribosylating activity of ExoS. Microbiology (Reading, Engl.) 146: 2531-2541.
24. Sun Y, Karmakar M, Taylor PR, Rietsch A, Pearlman E. 2012. ExoS and ExoT ADP ribosyltransferase activities mediate Pseudomonas aeruginosa keratitis by promoting neutrophil apoptosis and bacterial survival. J. Immunol. 188: 1884-1895.
25. Radke J, Pederson KJ, Barbieri JT. 1999. Pseudomonas aeruginosa exoenzyme S is a biglutamic acid ADP-ribosyltransferase. Infect. Immun. 67: 1508-1510.
26. DiMango E, Zar HJ, Bryan R, Prince A. 1995. Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J. Clin. Invest. 96: 2204-2210. http://dx. doi. org/10. 1172/JCI118275.
27. Rocha CL, Coburn J, Rucks EA, Olson JC. 2003. Characterization of Pseudomonas aeruginosa exoenzyme S as a bifunctional enzyme in J774A. 1 macrophages. Infect. Immun. 71: 5296-5305. http://dx. doi. org/10. 1128/IAI. 71. 9. 5296-5305. 2003.
28. Pederson KJ, Barbieri JT. 1998. Intracellular expression of the ADPribosyltransferase domain of Pseudomonas aeruginosa exoenzyme S is cytotoxic to eukaryotic cells. Mol. Microbiol. 30: 751-759. http://dx. doi. org/10. 1046/j. 1365-2958. 1998. 01106. x.
29. Criss AK, Katz BZ, Seifert HS. 2009. Resistance of Neisseria gonorrhoeae to non-oxidative killing by adherent human polymorphonuclear leucocytes. Cell. Microbiol. 11: 1074-1087.
30. Ganesan AK, Vincent TS, Olson JC, Barbieri JT. 1999. Pseudomonas aeruginosa exoenzyme S disrupts Ras-mediated signal transduction by inhibiting guanine nucleotide exchange factor-catalyzed nucleotide exchange. J. Biol. Chem. 274: 21823-21829. http://dx. doi. org/10. 1074/jbc. 274. 31. 21823.
31. Maresso AW, Deng Q, Pereckas MS, Wakim BT, Barbieri JT. 2007. Pseudomonas aeruginosa ExoS ADP-ribosyltransferase inhibits ERM phosphorylation. Cell. Microbiol. 9: 97-105. http://dx. doi. org/10. 1111/j. 1462-5822. 2006. 00770. x.
32. Alvarez-Dominguez C, Stahl PD. 1999. Increased expression of Rab5a correlates directly with accelerated maturation of Listeria monocytogenes phagosomes. J. Biol. Chem. 274: 11459-11462. http://dx. doi. org/10. 1074/jbc. 274. 17. 11459.
33. Barbieri AM, Sha Q, Bette-Bobillo P, Stahl PD, Vidal M. 2001. ADPribosylation of Rab5 by ExoS of Pseudomonas aeruginosa affects endocytosis. Infect. Immun. 69: 5329-5334. http://dx. doi. org/10. 1128/IAI. 69. 9. 5329-5334. 2001.
34. Evdokimov AG, Tropea JE, Routzahn KM, Waugh DS. 2002. Crystal structure of the Yersinia pestis GTPase activator YopE. Protein Sci. 11: 401-408.
35. Würtele M, Wolf E, Pederson KJ, Buchwald G, Ahmadian MR, Barbieri JT, Wittinghofer A. 2001. How the Pseudomonas aeruginosa ExoS toxin downregulates Rac. Nat. Struct. Biol. 8: 23-26. http://dx. doi. org/10. 1038/83007.
36. Pederson KJ, Vallis AJ, Aktories K, Frank DW, Barbieri JT. 1999. The amino-terminal domain of Pseudomonas aeruginosa ExoS disrupts actin filaments via small-molecular-weight GTP-binding proteins. Mol. Microbiol. 32: 393-401. http://dx. doi. org/10. 1046/j. 1365-2958. 1999. 01359. x.
37. Matz C, Moreno AM, Alhede M, Manefield M, Hauser AR, Givskov M, Kjelleberg S. 2008. Pseudomonas aeruginosa uses type III secretion system to kill biofilm-associated amoebae. ISME J 2: 843-852. http://dx. doi. org/10. 1038/ismej. 2008. 47.
38. Rucks EA, Fraylick JE, Brandt LM, Vincent TS, Olson JC. 2003. Cell line differences in bacterially translocated ExoS ADP-ribosyltransferase substrate specificity. Microbiology (Reading, Engl.) 149: 319-331. http://dx. doi. org/10. 1099/mic. 0. 25985-0.
39. Angus AA, Evans DJ, Barbieri JT, Fleiszig SMJ. 2010. The ADPExoS ribosylation domain of Pseudomonas aeruginosa ExoS is required for membrane bleb niche formation and bacterial survival within epithelial cells. Infect. Immun. 78: 4500-4510. http://dx. doi. org/10. 1128/IAI. 00417-10.
40. Olson JC, McGuffie EM, Frank DW. 1997. Effects of differential expression of the 49-kilodalton exoenzyme S by Pseudomonas aeruginosa on cultured eukaryotic cells. Infect. Immun. 65: 248-256.
41. Ottmann C, Yasmin L, Weyand M, Veesenmeyer JL, Diaz MH, Palmer RH, Francis MS, Hauser AR, Wittinghofer A, Hallberg B. 2007. Phosphorylation-independent interaction between 14-3-3 and exoenzyme S: from structure to pathogenesis. EMBO J. 26: 902-913. http://dx. doi. org/10. 1038/sj. emboj. 7601530.
42. Fraylick JE, La Rocque JR, Vincent TS, Olson JC. 2001. Independent and coordinate effects of ADP-ribosyltransferase and GTPase-activating activities of exoenzyme S on HT-29 epithelial cell function. Infect. Immun. 69: 5318-5328. http://dx. doi. org/10. 1128/IAI. 69. 9. 5318-5328. 2001.
43. Vogel HJ, Bonner DM. 1956. Acetylornithinase of Escherichia coli: partial purification and some properties. J. Biol. Chem. 218: 97-106.
44. Nicas TI, Iglewski BH. 1984. Isolation and characterization of transposon-induced mutants of Pseudomonas aeruginosa deficient in production of exoenzyme S. Infect. Immun. 45: 470-474.
45. Comolli JC, Hauser AR, Waite L, Whitchurch CB, Mattick JS, Engel JN. 1999. Pseudomonas aeruginosa gene products PilT and PilU are required for cytotoxicity in vitro and virulence in a mouse model of acute pneumonia. Infect. Immun. 67: 3625-3630.
46. Diaz MH, Shaver CM, King JD, Musunuri S, Kazzaz JA, Hauser AR. 2008. Pseudomonas aeruginosa induces localized immunosuppression during pneumonia. Infect. Immun. 76: 4414-4421. http://dx. doi. org/10. 1128/IAI. 00012-08.
47. Howell HA, Logan LK, Hauser AR. 2013. Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia. mBio 4(2): e00032-13.